Amgen Inc (AMGN) 160.41 $AMGN
Final Glance: Biotechnology companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Midday Glance: Biotechnology companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Early Glance: Biotechnology companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
PR Newswire - Tue Nov 04, 8:00AM CST
Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
AMGN: 160.41 (-1.15)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.71 (-0.42), MRK: 59.37 (+0.45), AMGN: 160.41 (-1.15), KPTI: 40.40 (-2.90)
Next Support Level for Amgen (AMGN) is $159.52
Comtex SmarTrend(R) - Mon Nov 03, 11:41AM CST
Amgen (NASDAQ:AMGN) has opened bearishly below the pivot of $162.75 today and has reached the first level of support at $160.85. Investors may be interested in a cross of the next downside pivot targets of $159.52 and $156.29.
AMGN: 160.41 (-1.15)
Why Amgen, Inc. Stock Surged 15% in October
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 03, 9:40AM CST
AMGN data by YCharts What: Shares of biopharmaceutical behemoth Amgen surged 15% in the month of October, based on data from S&P Capital IQ , primarily following a positive earnings report and amid speculation that the company could...
AMGN: 160.41 (-1.15)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.61 (+0.32), BIIB: 322.06 (+0.81), AMGN: 160.41 (-1.15)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (+0.07), PFE: 30.28 (+0.09), AMGN: 160.41 (-1.15), NVS: 91.93 (+0.23)
The Untouchables: Where Even Activist Investors Fear to Tread
at The Street - Fri Oct 31, 1:58PM CDT
Up to now, companies in highly regulated industries were safe from activists.
AT: 2.18 (-0.04), ETR: 82.47 (-1.38), ACT: 245.32 (-2.18), CBRL: 117.33 (+1.56), EXC: 36.47 (+0.07), ITC: 39.67 (-0.08), AOL: 43.59 (+0.13), DYN: 31.38 (+0.24), AMGN: 160.41 (-1.15), AAPL: 108.60 (-0.80)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 23.92 (+0.04), GILD: 109.72 (-0.26), SHPG: 195.62 (-0.87), AMGN: 160.41 (-1.15), ABBV: 62.66 (-0.59)
Aegerion Q3 Loss Wider than Expected, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 10:32AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported third-quarter 2014 net loss per share of 20 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents.
AMGN: 160.41 (-1.15), AEGR: 21.14 (+0.21), SNY: 45.49 (-0.29), REGN: 372.39 (-22.87)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 322.06 (+0.81), BBH: 115.11 (-1.11), AMGN: 160.41 (-1.15), CELGZ: 3.62 (+0.02)
Next Resistance Level for Amgen (AMGN) is $161.31
Comtex SmarTrend(R) - Thu Oct 30, 12:26PM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $158.50 today and have reached the first resistance level of $160.10. Investors may be interested in a cross of the next upside pivot targets of $161.31 and $164.12.
AMGN: 160.41 (-1.15)
Final Glance: Biotechnology companies
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Midday Glance: Biotechnology companies
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Early Glance: Biotechnology companies
AP - Tue Nov 04, 9:49AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 109.72 (-0.26), AMGN: 160.41 (-1.15), CELG: 105.75 (-1.66)
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
PR Newswire - Tue Nov 04, 8:00AM CST
Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
AMGN: 160.41 (-1.15)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.71 (-0.42), MRK: 59.37 (+0.45), AMGN: 160.41 (-1.15), KPTI: 40.40 (-2.90)
Next Support Level for Amgen (AMGN) is $159.52
Comtex SmarTrend(R) - Mon Nov 03, 11:41AM CST
Amgen (NASDAQ:AMGN) has opened bearishly below the pivot of $162.75 today and has reached the first level of support at $160.85. Investors may be interested in a cross of the next downside pivot targets of $159.52 and $156.29.
AMGN: 160.41 (-1.15)
Why Amgen, Inc. Stock Surged 15% in October
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 03, 9:40AM CST
AMGN data by YCharts What: Shares of biopharmaceutical behemoth Amgen surged 15% in the month of October, based on data from S&P Capital IQ , primarily following a positive earnings report and amid speculation that the company could...
AMGN: 160.41 (-1.15)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.61 (+0.32), BIIB: 322.06 (+0.81), AMGN: 160.41 (-1.15)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (+0.07), PFE: 30.28 (+0.09), AMGN: 160.41 (-1.15), NVS: 91.93 (+0.23)
The Untouchables: Where Even Activist Investors Fear to Tread
at The Street - Fri Oct 31, 1:58PM CDT
Up to now, companies in highly regulated industries were safe from activists.
AT: 2.18 (-0.04), ETR: 82.47 (-1.38), ACT: 245.32 (-2.18), CBRL: 117.33 (+1.56), EXC: 36.47 (+0.07), ITC: 39.67 (-0.08), AOL: 43.59 (+0.13), DYN: 31.38 (+0.24), AMGN: 160.41 (-1.15), AAPL: 108.60 (-0.80)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 23.92 (+0.04), GILD: 109.72 (-0.26), SHPG: 195.62 (-0.87), AMGN: 160.41 (-1.15), ABBV: 62.66 (-0.59)
Aegerion Q3 Loss Wider than Expected, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 10:32AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported third-quarter 2014 net loss per share of 20 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents.
AMGN: 160.41 (-1.15), AEGR: 21.14 (+0.21), SNY: 45.49 (-0.29), REGN: 372.39 (-22.87)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 322.06 (+0.81), BBH: 115.11 (-1.11), AMGN: 160.41 (-1.15), CELGZ: 3.62 (+0.02)
Next Resistance Level for Amgen (AMGN) is $161.31
Comtex SmarTrend(R) - Thu Oct 30, 12:26PM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $158.50 today and have reached the first resistance level of $160.10. Investors may be interested in a cross of the next upside pivot targets of $161.31 and $164.12.
AMGN: 160.41 (-1.15)
